The AHA May 14 urged the Senate Finance Committee to take steps to strengthen the supply chain for essential pharmaceutical and other medical products. In comments to the committee for a hearing on supply chains, the AHA called for tariff exceptions to continue for pharmaceuticals and pharmaceutical products and that additional exceptions be added for medical devices and other critical care supplies.   
  
“Mitigating supply chain challenges requires diversifying where raw materials are sourced and where products are manufactured,” the AHA wrote. “Imposing tariffs that limit the U.S.’s ability to acquire constituent parts or finished medical and pharmaceutical products from abroad will hinder supply chain resiliency.”  
  
The AHA also urged Congress to reintroduce the Mapping America’s Pharmaceutical Supply Act, legislation that would create a plan for the Food and Drug Administration and the Department of Defense to map the U.S. pharmaceutical supply chain, and the Pharmaceutical Supply Chain Risk Assessment Act, a bill that would require a comprehensive risk assessment of the pharmaceutical supply chain. 

Related News Articles

Headline
A JAMA study published Aug. 20 found that nearly 63% of all U.S. drug production facilities from 2019 through 2024 were in counties where a weather disaster…
Headline
B. Braun Medical has voluntarily recalled two lots of Lactated Ringer’s Injection USP 1000 mL and 0.9% Sodium Chloride Injection USP 1000 mL IV fluids due to…
Headline
The White House Aug. 13 released an executive order directing the Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness…
Headline
The Food and Drug Administration has identified a Class I recall of Draeger SafeStar and TwinStar Filters due to a risk of misleading carbon dioxide readings.…
Headline
The Food and Drug Administration Aug. 8 announced an end to the national shortage of sodium chloride 0.9% IV solutions products. The agency said it continues…
Headline
The Food and Drug Administration Aug. 7 announced a new program to help improve the domestic pharmaceutical supply chain by increasing regulatory…